US Supplement Firm Touts COVID-19 Study, Kicks Off Promotional Campaign With Tae Bo Creator
Executive Summary
Todos Medical, warned in 2021 about COVID-19 claims, could prompt a second warning about linking Tollovid to the coronavirus with recent announcement of test results. Firm also has appointed VPs of marketing and of government affairs since FTC in April 2021 warned about claims on its website, its social media pages and in a store.
You may also be interested in...
US FTC Diagnoses Omicron Symptom: More Fraudulent COVID-19 Treatment Claims
Agency says emergence of Omicron variant spurred marketers of products and services from peptide therapy to herbal remedies, and from nasal irrigation to intravenous drips to make false COVID-19 claims.
Urged By US FDA To Boost Infant Formula Supply, Additional Providers Still Must Wait For Approval
Patricia Hansen, CFSAN’s Office of Nutrition and Food Labeling deputy director and John Verbeten, deputy director for Import Operations Enforcement laid out the FDA's new enforcement guidance, and urged businesses with available formula to wait for approval before distributing formula in the US.
House Appropriators Sound Off During FDA Hearing About Formula, More Consumer Health Issues
Before Agriculture/FDA subcommittee about FY2023 budget, Commissioner Robert Califf says FDA needs more resources to address unlisted fragrances in menstrual products and doesn’t have good regulatory options for hemp and kratom. His formula emergency comments leave members frustrated.